Literature DB >> 29604450

Changes in methylation within the STK32B promoter are associated with an increased risk for generalized anxiety disorder in adolescents.

Diana M Ciuculete1, Adrian E Boström2, Anna-Kaisa Tuunainen2, Farah Sohrabi2, Lara Kular3, Maja Jagodic3, Sarah Voisin4, Jessica Mwinyi2, Helgi B Schiöth2.   

Abstract

Generalized anxiety disorder (GAD) is highly prevalent among adolescents. An early detection of individuals at risk may prevent later psychiatric condition. Genome-wide studies investigating single nucleotide polymorphisms (SNPs) concluded that a focus on epigenetic mechanisms, which mediate the impact of environmental factors, could more efficiently help the understanding of GAD pathogenesis. We investigated the relationship between epigenetic shifts in blood and the risk to develop GAD, evaluated by the Development and Well-Being Assessment (DAWBA) score, in 221 otherwise healthy adolescents. Our analysis focused specifically on methylation sites showing high inter-individual variation but low tissue-specific variation, in order to infer a potential correlation between results obtained in blood and brain. Two statistical methods were applied, 1) a linear model with limma and 2) a likelihood test followed by Bonferroni correction. Methylation findings were validated in a cohort of 160 adults applying logistic models against the outcome variable "anxiety treatment obtained in the past" and studied in a third cohort with regards to associated expression changes measured in monocytes. One CpG site showed 1% increased methylation in adolescents at high risk of GAD (cg16333992, padj. = 0.028, estimate = 3.22), as confirmed in the second cohort (p = 0.031, estimate = 1.32). The identified and validated CpG site is located within the STK32B promoter region and its methylation level was positively associated with gene expression. Gene ontology analysis revealed that STK32B is involved in stress response and defense response. Our results provide evidence that shifts in DNA methylation are associated with a modulated risk profile for GAD in adolescence.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  DNA methylation; Epigenetics; Generalized anxiety disorder; STK32B

Mesh:

Substances:

Year:  2018        PMID: 29604450     DOI: 10.1016/j.jpsychires.2018.03.008

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  5 in total

Review 1.  Challenges in Analyzing Functional Epigenetic Data in Perspective of Adolescent Psychiatric Health.

Authors:  Diana M Manu; Jessica Mwinyi; Helgi B Schiöth
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

2.  meQTL and ncRNA functional analyses of 102 GWAS-SNPs associated with depression implicate HACE1 and SHANK2 genes.

Authors:  Diana M Ciuculete; Sarah Voisin; Lara Kular; Jörgen Jonsson; Mathias Rask-Andersen; Jessica Mwinyi; Helgi B Schiöth
Journal:  Clin Epigenetics       Date:  2020-07-02       Impact factor: 6.551

3.  Longitudinal DNA methylation changes at MET may alter HGF/c-MET signalling in adolescents at risk for depression.

Authors:  Diana M Ciuculete; Sarah Voisin; Lara Kular; Nipuni Welihinda; Jörgen Jonsson; Maja Jagodic; Jessica Mwinyi; Helgi B Schiöth
Journal:  Epigenetics       Date:  2019-12-19       Impact factor: 4.528

4.  Relationship between intestinal flora, inflammation, BDNF gene polymorphism and generalized anxiety disorder: A clinical investigation.

Authors:  Yuanyuan Cheng; Yue Wang; Wen Zhang; Junbo Yin; Jicheng Dong; Jintong Liu
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

5.  MAPT haplotype-stratified GWAS reveals differential association for AD risk variants.

Authors:  Samantha L Strickland; Joseph S Reddy; Mariet Allen; Aurelie N'songo; Jeremy D Burgess; Morgane M Corda; Travis Ballard; Xue Wang; Minerva M Carrasquillo; Joanna M Biernacka; Gregory D Jenkins; Shubhabrata Mukherjee; Kevin Boehme; Paul Crane; John S Kauwe; Nilüfer Ertekin-Taner
Journal:  Alzheimers Dement       Date:  2020-05-13       Impact factor: 16.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.